Highlights of Cardiovascular Disease Studies Presented at the 2021 American Heart Association Scientific Sessions
- PMID: 35080715
- PMCID: PMC8790010
- DOI: 10.1007/s11883-022-00985-0
Highlights of Cardiovascular Disease Studies Presented at the 2021 American Heart Association Scientific Sessions
Abstract
Purpose of review: This review highlights major studies across a broad array of topics presented at the virtual 2021 American Heart Association (AHA) Scientific Sessions.
Recent findings: Assessed studies examine a remotely delivered hypertension and lipid program in 10,000 patients across a diverse healthcare network; a cluster-randomized trial of a village doctor-led intervention for hypertension control; empagliflozin in heart failure with preserved ejection fraction (EMPEROR-Preserved); efficacy and safety of empagliflozin in hospitalized heart failure patients (EMPULSE); icosapent ethyl versus placebo in outpatients with coronavirus disease 2019 (PREPARE-IT 2); clinical safety, pharmacokinetics, and low-density lipoprotein cholesterol-lowering efficacy of MK-0161, an oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor; and effects of aspirin on dementia and cognitive impairment in the ASCEND trial. Research presented at the 2021 AHA Scientific Sessions emphasized the importance of interventions for cardiovascular disease prevention.
Keywords: Aspirin; Atherosclerotic cardiovascular disease; Cardiovascular prevention; Empagliflozin; Heart failure.
© 2022. This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.
Conflict of interest statement
References
-
- •• Anker SD, Butler J, Filippatos G et al. Empagliflozin in heart failure with a preservedejection fraction. N Engl J Med 2021; 385(16):1451–1461. (In a randomized trial of 5988 heart failure patients with left ventricular ejection fraction >40%, empagliflozin (compared with placebo) was associated with a significant risk reduction in the composite endpoint of cardiovascular death and first hospitalization for heart failure.) - PubMed
-
- Jain V, Al Rifai M, Mahtta D, Liu J, Hussain A, Virani SS. Highlights from studies presented at the virtual American College of Cardiology Scientific Sessions 2021: Staying updated with the latest advancements in prevention. Curr Atheroscler Rep. 2021;23(9):50. doi: 10.1007/s11883-021-00952-1. - DOI - PMC - PubMed
-
- Jia X, Lee MT, Ramsey DJ et al. Facility-level variation in reported statin-associated side effects among patients with atherosclerotic cardiovascular disease-perspective from the Veterans Affair healthcare system. Cardiovasc Drugs Ther 2021; Online ahead of print. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous